| |
 |
This is the category page. Below are all of the research programs that are associated with it
- Lung Cancer -
ECOG #E1505: A PHASE III RANDOMIZED TRIAL OF ADJUVANT CHEMOTHERAPY WITH OR WITHOUT BEVACIZUMAB FOR PATIENTS WITH COMPLETELY RESECTED STAGE IB (> 4cm)–IIIA NON-SMALL CELL LUNG CANCER (NSCLC)(2_20070906_118)
The use of an investigational drug bevacizumab, the first 4 cycles, day one delivered immediately after completion of chemotherapy. Then, continue every three weeks for up to one year (measured from date of first protocol treatment). All patients will be assigned to one of three chemotherapy regimens. There will be 2 Arms to the study. Arm A will received one of the three chemotherapy regimens with no bevacizumab; and Arm B of the study will received on the three chemotherapy regimens plus bevacizumab.
- Lung Cancer -
NCCTG #N0626 – A PHASE II RANDOMIZED STUDY OF PEMETREXED WITH SORAFENIB VERSUS PEMETREXED ALONE AS SECOND-LINE THERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER
(1_20071202_118)
This is a Phase II randomized study that will use FDA approved drugs, Pemetrexed Disodium/ALIMTA and Sorafenib/Nexavar. Participants will be randomized to one of two arms. One Arm will receive Pemetrexed and Sorafenib and the other will receive Pemetrexed alone. Each cycle will consist of 21 days and participants will continue with randomized drug until unacceptable events, other treatment options become available, disease progression or participant withdrawals from the study.
- Lung Cancer -
NCCTG: N0723 MARVEL: MARKER VALIDATION OF ERLOTINIB IN LUNG CANCER – A PHASE III BIOMARKER VALIDATION STUDY OF SECOND-LINE THERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) RANDOMIZED TO PEMETREXED VERSUS ERLOTINIB
(2_20090202_118)
This is a clinical trial for second-line treatment for advanced non-small cell lung cancer (NSCLC) using two FDA approved drugs, Erlotonib and Pemetrexed. Participant’s tumor sample will be sent to a central lab to review the pathology. Participants will than be randomized to be placed on either Arm A to receive Erlotinib daily; or Arm B to receive Pemetrexed day one of each cycle. A cycle will be every 21 days. Participants will remain on the study until disease progression or unacceptable toxicity. Participants can withdraw from the study at anytime.
- Lung Cancer-Stage 1:
CALGB-30506: A RANDOMIZED PHASE III TRIAL OF ADJUVANT THERAPY IN EARLY STAGE NON-SMALL CELL LUNG CANCER EVALUATING THE POTENTIAL UTILITY OF GENOMIC PROGNOSTIC MODEL TO IDENTIFY PATIENTS AS CANDIDATES FOR ADJUVANT CHEMOTHERAPY
(1_20090611_118)
This study is for patients with Stage 1, Non-Small Cell Lung Cancer. A laboratory test called Lung Metagene Score (LMS) will be performed on the tumor to collect information with the results to see if the tumor will recur by studying the tumor gene. Participants will be randomized into one of two arms. Arm 1- participants will be treated with standard of care, which is observation. Arm II - participants will receive 1 of 3 chemotherapy regimens appropriate for tumor type and doctors discretion. Participants may receive up to 4 courses which will repeat every 21 days. After completion of study treatment, all participants will be followed every 4 months for 2 years; and then every 6 months for 3 years.
- Study Closed to Accrual: Lung Cancer - NCCTG N0528 - A RANDOMIZED PHASE II STUDY OF GEMCITABINE AND CARBOPLATIN WITH OR WITHOUT AZD2171 AS FIRST-LINE THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER (2_20071107_118)
There will be 2 Arms to this study. Arm “A” will receive Gemcitabine days 1 & 8, Carboplatin day 1, and AZD2171 daily, which is a non-FDA approved drug, which is the study drug. Arm “B” will receive Gemcitabine days 1 & 8 and Carboplatin day 1. Each Arm will repeat every 21 days for a maximum of 6 cycles or until such time of unacceptable toxicity, disease progression, etc.
|
|
